1. RICERCA E INNOVAZIONE QUALITA E SVILUPPO Presentazione di Umberto Bertazzoni Siena, 12 dicembre 2005

2. Partner italiani valutati e selezionati (totali); Appartenenza Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

3. Partner italiani valutati e selezionati : 1.2 Biotechnology Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

4. Partner italiani valutati e selezionati (totali); Appartenenza Priority 1, Life Sciences; Secondo Bando Partner valutati Partner selezionati in lista di priorità

5. Partner italiani valutati e selezionati : 2.1 Major Diseases Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

6. Partner italiani valutati e selezionati : 2.3 Poverty Diseases Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

7. Quadro generale in negoziazione dei partecipanti e finanziamenti per tipo di partecipante e per paese nel primo bando della priorità 1

9. 0 5 10 15 20 25 30 35 40 Pub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELE IPNoESTREP Partner valutati Partner selezionati in lista di priorità Partner italiani valutati e selezionati : 1.2 Biotechnology Priority 1, Life Sciences; Secondo Bando

10. 0 5 10 15 20 25 30 35 Pub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELE IPNoESTREP Partner valutati Partner selezionati in lista di priorità Partner italiani valutati e selezionati : 2.1 Major Diseases Priority 1, Life Sciences; Secondo Bando

11. Appartenenza partecipanti italiani ai progetti in negoziazione terzo bando

12. in 223 projects (out of 417) 527 participants (some participants appear in more than one project) = 9.4 % of all participants (5611 in total) 43 different private companies (some appear in more than one project) Italian participation in financed projects (calls 1, 2 and 3 ; priority 1 ; fp6)

14. Innovative Medicines Long term objective: To increase the competitiveness of the European Pharmaceutical industry, and to foster Europe as the most attractive place for pharmaceutical R&D. Thereby enhancing access of innovative medicines to the benefit of patients and society. Aim: To remove major bottlenecks in the drug development process, as identified by industry, and where research is the key. Joint Technology Initiative

15. Innovative Medicines Initiative Industry (under the leadership of EFPIA) has identified the bottlenecks in agreement with key stakeholders: academia, regulatory agencies, patient organisations, clinical researchers, ethical experts, etc. A Strategic Research Agenda prioritising the research needs and how they should be implemented has been developed by panels of experts.

16. Innovative Medicines Initiative The Strategic Research Agenda will address bottlenecks in four main areas: Improved prediction – early indications of safety. Improved clinical performance – early indications of efficacy by use of biomarkers. Better knowledge management through collaboration – breaking information barriers at the interfaces. Bridging educational gaps – pre-clinical and clinical research and breaking barriers between disciplines.